Humana (NYSE:HUM) Given New $310.00 Price Target at Barclays

Humana (NYSE:HUMFree Report) had its price target cut by Barclays from $356.00 to $310.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have an equal weight rating on the insurance provider’s stock.

Several other research analysts also recently issued reports on HUM. Raymond James started coverage on Humana in a research note on Friday, March 22nd. They set a market perform rating for the company. Wells Fargo & Company cut their price target on Humana from $465.00 to $413.00 and set an overweight rating for the company in a research note on Tuesday, January 30th. Truist Financial reaffirmed a hold rating and set a $550.00 price target on shares of Humana in a research note on Friday, January 19th. The Goldman Sachs Group cut their price target on Humana from $515.00 to $450.00 and set a buy rating for the company in a research note on Friday, January 26th. Finally, Royal Bank of Canada cut their target price on shares of Humana from $507.00 to $415.00 and set an outperform rating for the company in a research note on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $472.16.

Get Our Latest Report on HUM

Humana Price Performance

Shares of NYSE HUM opened at $304.33 on Tuesday. The firm has a market capitalization of $36.72 billion, a P/E ratio of 15.35, a PEG ratio of 2.03 and a beta of 0.45. Humana has a one year low of $299.23 and a one year high of $541.21. The company’s fifty day moving average is $358.86 and its two-hundred day moving average is $439.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59.

Humana (NYSE:HUMGet Free Report) last issued its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). The company had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. Humana’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.62 earnings per share. Analysts forecast that Humana will post 16.04 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date is Wednesday, March 27th. Humana’s dividend payout ratio is currently 17.86%.

Insider Activity

In related news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the purchase, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently bought and sold shares of HUM. Rakuten Securities Inc. acquired a new stake in Humana during the 4th quarter worth approximately $25,000. Point72 Europe London LLP acquired a new stake in Humana during the 4th quarter worth approximately $26,000. Gradient Investments LLC increased its position in Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A acquired a new stake in Humana during the 4th quarter worth approximately $28,000. Finally, Sunbelt Securities Inc. acquired a new stake in Humana during the 1st quarter worth approximately $28,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.